Comparative selectivity studies against less-selective GHS compounds (GHRP-2, GHRP-6, hexarelin) to characterize receptor-binding profiles and downstream signalling specificity
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management, chronic weight management, and in the case of Wegovy, cardiovascular risk reduction in certain patients
Semaglutide 2.4 mg (Wegovy, FDA-approved for weight management) reports diarrhea in approximately 30% of patients in clinical trials according to the FDA prescribing information
Improper handling or use may result in risks
Johns bread (carob)(color), turmeric (color) and sodium copper chlorophyllin (color)
To understand why Retatrutide exists, its helpful to look at how peptide research has evolved